@article{099313693d654157b9fd56a2ab1c2996,
title = "Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis",
abstract = "For people enrolled in Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), we sought to examine whether variation exists in the baseline medical therapy of different geographic regions and if any variations in prescribing patterns were associated with physician specialty. Patients were grouped by location within the United States (US) and outside the US (OUS), which includes Canada, South America, Europe, South Africa, New Zealand, and Australia. When comparing US to OUS, participants in the US took fewer anti-hypertensive medications (1.9 ± 1.5 vs. 2.4 ± 1.4; P < .001) and were less likely to be treated with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (46% vs. 62%; P<.001), calcium channel antagonist (37% vs. 58%; P < .001), and statin (64% vs. 75%; P < .05). In CORAL, the identification of variations in baseline medical therapy suggests that substantial opportunities exist to improve the medical management of patients with atherosclerotic renal-artery stenosis. JAm Soc Hypertens 2015;9(6):443-452.",
keywords = "Antihypertensive medical therapy, Geography, Renovascular hypertension",
author = "Folt, {David A.} and Evans, {Kaleigh L.} and Sravya Brahmandam and Wencan He and Brewster, {Pamela S.} and Shipeng Yu and Murphy, {Timothy P.} and Cutlip, {Donald E.} and Dworkin, {Lance D.} and Kenneth Jamerson and William Henrich and Kalra, {Philip A.} and Sheldon Tobe and Ken Thomson and Andrew Holden and Rayner, {Brian L.} and Liliana Grinfeld and Haller, {Steven T.} and Cooper, {Christopher J.}",
note = "Funding Information: Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (Bethesda, MD) under Award Numbers U01HL072734, U01HL072735, U01HL072736, and U01HL072737. Dr Cooper and Ms Brewster have also received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health ( 5U01HL071556 ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Drugs for this study were provided by AstraZeneca, device support was provided by Cordis Corporation, and supplemental financial support was granted by both the Cordis Corporation and Pfizer, Inc . Publisher Copyright: Copyright {\textcopyright} 2015 American Society of Hypertension. All rights reserved.",
year = "2015",
doi = "10.1016/j.jash.2015.03.007",
language = "English (US)",
volume = "9",
pages = "443--452",
journal = "Journal of the American Society of Hypertension",
issn = "1933-1711",
publisher = "Elsevier Ireland Ltd",
number = "6",
}